(Adnkronos) - DÜSSELDORF, Germany, Dec. 6, 2022 /PRNewswire/ -- At today's Capital Markets Day, Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance. The company recorded a
Attractive growth projects, including new biologics orders in both High Value Solutions and Contract Manufacturing are underling Gerresheimer's position as a strategic partner for the global pharma and biotech industries. Gerresheimer's expertise and strong track record are enabling the company to accelerate sustainable, profitable growth by consistently increasing the revenue share of biologics solutions and injectables. In particular "ready-to-fill" solutions in syringes and vials are driving growth in High Value Solutions while Medical Devices are boosting growth in the area of Contract Manufacturing.
More information:https://www.gerresheimer.com/en/company/newsroom/corporate-news
For further information: http://www.presseportal.de/nr/9072/dokument?langid=2
Melanie EggerstedtDirector Corporate CommunicationsT +49 171 655 Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
View original content:https://www.prnewswire.co.uk/news-releases/gerresheimer-to-expand-significantly-in-high-value-solutions-and-further-accelerates-its-sustainable-profitable-growth-301695877.html